SGEN and GMAB Related Headlines

Oct 22, 2023 10:30AM TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

Sep 5, 2023 05:35AM Seagen (SGEN) and Genmab (GMAB) Report TIVDAK Met its Primary Endpoint of Improved Overall Survival

Sep 4, 2023 03:00PM Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone

SGEN and GMAB Related Press Releases

Oct 22, 2023 10:30AM TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

Sep 4, 2023 03:00PM Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone

SGEN and GMAB Related SEC Filings